Abstract
Objective Reports of cerebral sinus and venous thrombosis (CVT) after ChAdOx1 vaccination against SARS-CoV-2 have raised safety concerns. We aimed to estimate the incidence of CVT within one month from first dose administration and the frequency of vaccine-induced immune thrombotic thrombocytopenia (VITT) as the underlying mechanism after vaccination with BNT162b2, ChAdOx1, and mRNA-1273, in Germany.
Methods A web-based questionnaire was e-mailed to all Departments of Neurology. We asked to report cases of CVT within one month of a COVID-19 vaccination. Other cerebral events could also be reported. Incidence rates of CVT were calculated by using official statistics of nine German States.
Results A total of 45 CVT cases were reported. In addition, 9 primary ischemic strokes, 4 primary intracerebral hemorrhages, and 4 other neurological events were recorded. Of the CVT patients, 35 (77.8%) were female, and 36 (80.0%) were below the age of 60 years. Fifty-three events were observed after vaccination with ChAdOx1 (85.5%), 9 after BNT162b2 (14.5%), and none after mRNA-1273 vaccination. After 7,126,434 first vaccine doses, the incidence rate of CVT within one month from first dose administration was 6.5 (95% CI, 4.4-9.2) per 100,000 person-years for all vaccines and 17.9 (11.8-26.1) for ChAdOx1 (after 2,320,535 ChAdOx1 first doses). The adjusted incidence rate ratio was 9.68 (3.46-34.98) for ChAdOx1 compared to mRNA-based vaccines and 3.14 (1.22-10.65) for women compared to non-women. In 26/45 patients with CVT (57.8%), VITT was graded highly probable.
Conclusions Given an incidence of 0.22–1.75 per 100,000 person-years for CVT in the general population, these findings point towards a higher risk for CVT after ChAdOx1 vaccination, especially for women.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare the following competing interests: JBS reports (outside the present study) honoraria from advisory boards or oral presentations by Biogen, Novartis, and Grifols. He receives grants from the German Research Council (DFG), the German Ministry of Education and Research (BMBF), and the European Commission. PB serves as editor-in-chief for DGNeurologie. HCD reports outside of the present study: received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from: Abbott, BMS, Boehringer Ingelheim, Daiichi-Sankyo, Novo-Nordisk, Pfizer, Portola and WebMD Global. Financial support for research projects was provided by Boehringer Ingelheim. HCD received research grants from the German Research Council (DFG), German Ministry of Education and Research (BMBF), European Union, NIH, Bertelsmann Foundation, and Heinz-Nixdorf Foundation. HCD serves as editor of Neurologie up2date, Info Neurologie & Psychiatrie, Arzneimitteltherapie, as co-editor of Cephalalgia and on the editorial board of Lancet Neurology. HCD chairs the Treatment Guidelines Committee of the German Society of Neurology and contributed to the EHRA and ESC guidelines for the treatment of AF. CG received (outside the submitted work) funding from German Research Council (DFG), European Union, Federal Ministry of Education and Research (BMBF), German Statutory Pension Insurance Scheme (RV Nord), National Innovation Fund, Wegener Foundation, and Schilling Foundation. CG reports (outside the submitted work) personal fees from Amgen, Boehringer Ingelheim, Daiichi Sankyo, Abbott, Prediction Biosciences, Novartis, and Bayer. AG reports grants from Deutsche Forschungsgemeinschaft, personal fees and non-financial support from Aspen, grants from Ergomed, grants and non-financial support from Boehringer Ingelheim, personal fees from Bayer Vital, grants from Rovi, grants from Sagent, personal fees from Chromatec, personal fees and nonfinancial support from Instrumentation Laboratory, grants and personal fees from Macopharma, grants from Portola, grants from Biokit, personal fees from Sanofi-Aventis, grants from Fa. Blau Farmaceutics, grants from Prosensa/Biomarin, grants and other from DRK-BSD NSTOB, grants from DRK-BSD Baden-Wuertemberg/Hessen, personal fees and non-financial support from Roche, personal fees from GTH e.V., grants from Deutsche Forschungsgemeinschaft, outside the submitted work. In addition, AG reports having a patent, Application no. 2021032220550000DE, pending. CK serves as a medical advisor on genetic testing reports to Centogene and on the scientific advisory board of Retromer Therapeutics and as an Associate Editor for Annals of Neurology. MP reports being partially funded by a research grant from Novartis Pharma for a self-initiated research project, unrelated to this work, on migraine remission. MP further reports being awarded a research grant from the Center for Stroke Research Berlin (private donations) for a self-initiated project unrelated to this work on causal diagrams. SP received (all outside the submitted work) research grants from BMS/Pfizer, Daiichi Sankyo, European Union, German Federal Joint Committee Innovation Fund, and German Federal Ministry of Education and Research, and speakers honoraria/consulting fees from AstraZeneca, Bayer, Boehringer-Ingelheim, BMS/Pfizer, Daiichi Sankyo, Portola, and Werfen. RR reports outside of the submitted work to have received research funds from the German Ministry of Education and Research, German Joint Committee (GBA) and the German Ministry of Health. HS reports outside of the submitted work to have received speaker's honoraria from Bayer, Boehringer Ingelheim, and Teva. TT reports grants from Deutsche Forschungsgemeinschaft, during the conduct of the study; personal fees and other from Bristol Myers Squibb, personal fees and other from Pfizer, personal fees from Bayer, personal fees and other from Chugai Pharma, other from Novo Nordisk, personal fees from Novartis, other from Daichii Sankyo, outside the submitted work. TK reports outside of the submitted work to have received research funds from the German Joint Committee and the German Ministry of Health; he has received personal compensation from Eli Lilly & Company, Teva, Total S.E., and the BMJ.
Funding Statement
There was no specific funding for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was approved by the Ethics Committee (Vote-No. 142/21, Ethics Committee of the Medical Faculty at RWTH University). Data protection and privacy conformity has been confirmed by the Data Protection Officer and the Information Security Officer of RWTH Aachen University Hospital.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Members of the Study Group, see appendix
In this revision, we restructured the results section, tables, and figures; reported more accurately some details; focused our paper on more specific findings; changed the order of the authors; and edited the text.
Data Availability
Due to the votes that we received for ethics and data protection and privacy conformity for this survey, we will not be able to share data that contain information about the center, the age and the sex of the patient.
